ArticleSurgical case reports2026
Synchronous Double Primary Hepatocellular Carcinoma and Intrahepatic Cholangiocarcinoma: A Case Report.
Article in Surgical case reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionHepatocellular carcinoma (HCC) and intrahepatic cholangiocarcinoma (iCCA) are the most common and second most common primary liver cancers, respectively. In contrast, double primary hepatic cancer (DPHC), the synchronous occurrence of these two tumors in different locations of the liver, is an uncommon pathology, occurring in less than 0.8% of all liver malignancies. CASE PRESENTATION: A man in his 70s was referred to our department for the treatment of multiple liver tumors. He had previously been treated with a direct-acting antiviral agent for chronic liver disease due to hepatitis C virus infection and alcohol consumption. His carbohydrate antigen 19-9 (CA19-9) and des-γ-carboxy prothrombin levels were 36058 U/mL and 159 mAU/mL, respectively. Imaging studies revealed two separate lesions with different contrast features in segments VIII (SVIII, 2.5 cm in size) and IV/II/III (SIV/II/III, 3.5 cm). Therefore, the preoperative diagnosis was DPHC, consistent with HCC in SVIII and iCCA in SIV/II/III. The patient underwent an extended left hemihepatectomy with regional lymph node dissection and cholecystectomy, and DPHC was confirmed histologically.
conclusionsAccurate diagnoses and appropriate therapeutic strategies are essential for patients presenting with multiple liver tumors showing heterogeneous imaging features and elevated CA19-9 levels.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.